Lineage, Inc. Common Stock (LINE)vsUnited States Cellular Preferred 5.500% due 2070 (UZE)
LINE
Lineage, Inc. Common Stock
$37.52
+1.93%
REAL ESTATE · Cap: $9.41B
UZE
United States Cellular Preferred 5.500% due 2070
$16.43
-0.18%
REAL ESTATE · Cap: $2.74B
Smart Verdict
WallStSmart Research — data-driven comparison
UZE leads profitability with a 0.0% profit margin vs -3.1%. LINE earns a higher WallStSmart Score of 35/100 (F).
LINE
Avoid35
out of 100
Grade: F
UZE
Avoid29
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Every $100 of equity generates 24 in profit
Areas to Watch
0.8% revenue growth
0.0% earnings growth
Operating margin of 3.7%
Elevated debt levels
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : LINE
The strongest argument for LINE centers on Price/Book.
Bull Case : UZE
The strongest argument for UZE centers on Return on Equity.
Bear Case : LINE
The primary concerns for LINE are Revenue Growth, EPS Growth, Operating Margin.
Bear Case : UZE
The primary concerns for UZE are Revenue Growth, EPS Growth, Profit Margin.
Key Dynamics to Monitor
LINE profiles as a turnaround stock while UZE is a value play — different risk/reward profiles.
LINE is growing revenue faster at 0.8% — sustainability is the question.
LINE generates stronger free cash flow (186M), providing more financial flexibility.
Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LINE scores higher overall (35/100 vs 29/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lineage, Inc. Common Stock
REAL ESTATE · REIT - INDUSTRIAL · USA
Lineage, Inc. (Ticker: LINE) is a pioneering biotechnology firm dedicated to regenerative medicine, focusing on next-generation cell therapies targeting ocular diseases, spinal cord injuries, and various cancers. With its proprietary technologies and robust strategic collaborations, Lineage is at the forefront of developing transformative treatment options that aim to improve patient outcomes significantly. The company's commitment to enhancing its diverse product pipeline and expediting clinical trials makes it an attractive investment opportunity for institutional investors seeking exposure in the rapidly evolving healthcare landscape.
Visit Website →United States Cellular Preferred 5.500% due 2070
REAL ESTATE · REIT - RESIDENTIAL · USA
United States Cellular Preferred 5.500% due 2070 offers a strategic investment within the telecommunications sector, featuring a stable fixed dividend yield of 5.500%. As a preferred equity security of United States Cellular Corporation, it reflects the company's commitment to providing reliable income amidst market fluctuations. The long maturity until 2070 affords institutional investors the potential for capital appreciation while benefiting from the company's ongoing initiatives to improve operational efficiency and grow its customer base. With a forward-looking approach to navigating industry challenges, United States Cellular is well-positioned to deliver sustainable shareholder value, enhancing the appeal of this preferred stock for yield-focused investment strategies.
Visit Website →Compare with Other REIT - INDUSTRIAL Stocks
Want to dig deeper into these stocks?